Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

News Conference News AHA 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

November 12, 2025

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

November 14, 2024

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

What’s Going to Be Hot at AHA 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

November 07, 2023

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

November 16, 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

News Conference News AHA 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

November 15, 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

News Conference News AHA 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Michael O'Riordan

November 14, 2020

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

TiCAB: Ticagrelor No Help for Preventing Graft Failure Post-CABG

News Conference News AHA 2018

TiCAB: Ticagrelor No Help for Preventing Graft Failure Post-CABG

November 13, 2018

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

News Conference News AHA 2018

Very EARLY Invasive Angiography in NSTE ACS Patients Reduces Risk of Recurrent Ischemia

Michael O'Riordan

November 11, 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

November 10, 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

November 10, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

November 16, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.